About Moderna
Moderna news and updates
Moderna Therapeutics Inc. is developing mRNA
Elsewhere in the pipeline, Moderna is developing a dual COVID-19 and flu booster shot as well as a solo seasonal flu vaccine called mRNA-1010.
Jan 1, 2022 | fiercebiotech.comModerna Therapeutics Inc. expands offices to Latin America
Moderna Inc. has signed a deal with a Uruguayan pharmaceutical company in a bid to expand its reach across Latin America.
Jan 1, 2022 | bloomberg.comModerna Therapeutics Inc. is developing Covid-19 vaccine using mRNA technology in the Covid-19 pandemic on Dec 4th 20'.
Then, Moderna developed a Covid-19 vaccine using mRNA technology in the Covid-19 pandemic.
Jan 1, 2020 | koreabiomed.comModerna Therapeutics Inc. will partner with Gavi on Oct 29th 22'.
Moderna Inc on Friday announced a pact with the GAVI vaccine alliance to supply a further 56.5 million doses of its COVID-19 vaccine in the second quarter of next year to low- and middle-income countries.
Jan 1, 2021 | yahoo.comModerna Therapeutics Inc. launched single-shot vaccine booster for Covid on Aug 23rd 21'.
The shares of Moderna are up by more than 8% today after the company announced the launch of its single-shot vaccine booster for Covid and flu.
Jan 1, 2021 | yahoo.comModerna Therapeutics Inc. will develop COVID-19 vaccine on Mar 1st 22'.
Moderna will begin testing a COVID-19 vaccine that targets both the original coronavirus strain and the omicron variant, announcing Thursday trials in the U.S. and U.K. that will assess its efficacy in people who have already received boosters.
Jan 1, 2022 | healthcaredive.comModerna Therapeutics Inc. partners with Bill & Melinda Gates Foundation
"Moderna Therapeutics Inc. is very pleased to be partnering with IAVI and the Bill & Melinda Gates Foundation to apply its mRNA technology in the setting of HIV.
Jan 1, 2022 | modernatx.comModerna Therapeutics Inc. partners with Adium Pharma
Biotechnology company Moderna, Inc. ( NASDAQ: MRNA ) has signed a distribution service agreement with Uruguay-based pharmaceutical firm Adium Pharma for the sale of its COVID-19 vaccine, Spikevax, in Latin America.
Jan 1, 2022 | tipranks.comAdium Pharma SA partners with Moderna Therapeutics Inc.
“Adium Pharma SA is delighted to partner with Moderna to bring the COVID-19 vaccine for its Latin American population.
Jan 1, 2022 | adiumpharma.comModerna Therapeutics Inc. is developing Covid/influenza vaccine
Covid-19 is another one on the list, and Moderna is currently working on an omicron-specific booster dose for its current vaccine, as well as a combination Covid/influenza vaccine.
Jan 1, 2022 | forbes.comModerna Therapeutics Inc. increases headcount by 150
Moderna will create more than 150 new jobs over the next two years.
Jan 1, 2022 | georgia.govModerna Therapeutics Inc. expanded facilities to Kenya on Mar 14th 22'.
Moderna Inc said on Monday it would set up a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots.
Jan 1, 2022 | kdal610.comModerna Therapeutics Inc. invests into assets : facility in the amount of $500M in Kenya
Moderna plans to invest $500 million to produce messenger RNA, the technology underlying its Covid vaccines, at the facility in Kenya.
Jan 1, 2022 | cnbc.comCaribPR Wire partners with Moderna Therapeutics Inc.
“CaribPR Wire is delighted to partner with Moderna to help patients, physicians and governments in this effort against COVID-19.
Jan 1, 2022 | caribpr.comModerna Therapeutics Inc. invested into assets : mRNA manufacturing facility in the amount of $500M in Africa on Mar 14th 22'.
In Africa, Moderna has pledged up to $500 million to build an mRNA manufacturing facility that could eventually make up to 500 million doses annually at the 50-µg dose level.
Jan 1, 2022 | fiercepharma.comModerna Therapeutics Inc. launched updated patent enforcement policy on Mar 10th 22'.
Moderna Inc. (Nasdaq: MRNA) announced an updated patent enforcement policy this week, saying that it would "never enforce its patents for Covid-19 vaccines" against manufacturers in 92 low- and middle-income countries, as defined by the Gavi COVAX Advance Market Commitment.
Jan 1, 2022 | bizjournals.comModerna Therapeutics Inc. has issues with patents for their Covid-19 vaccines
Alnylam Pharmaceuticals Inc. said it had filed lawsuits against Pfizer Inc. and Moderna Inc., alleging that the companies had infringed its patents for their Covid-19 vaccines.
Jan 1, 2022 | bloomberglaw.comModerna Therapeutics Inc. launches mRNA Access program to offer researchers the use of Moderna's mRNA technology
Second, Moderna will launch its mRNA Access program to offer researchers the use of Moderna's mRNA technology to explore new vaccines against emerging or neglected infectious diseases.
Jan 1, 2022 | pharmanewsintel.comHenderson retires from Moderna Therapeutics Inc.
Moderna announced in late 2020 that Henderson would retire after joining the Cambridge, Mass.-based company two years earlier.
Jan 1, 2022 | bloomberglaw.comModerna Therapeutics Inc. is developing mRNA vaccines for 15 infectious diseases
Moderna has announced plans to develop mRNA vaccines for 15 infectious diseases — and it’s giving researchers across the globe access to its technology to create their own shots for countless other diseases.
Jan 1, 2022 | freethink.comModerna Therapeutics Inc. has issues with alleged infringements of its patent on biodegradable cationic lipids
Alnylam Pharmaceuticals Inc. has filed suits against both Pfizer Inc. and Moderna Inc. over alleged infringements of its patent on biodegradable cationic lipids that it said "are foundational to the success of the mRNA COVID-19 vaccines."
Jan 1, 2022 | bioworld.comAlnylam Pharmaceuticals, Inc. filed suit against Moderna Therapeutics Inc. on Mar 17th 22'.
Alnylam Pharmaceuticals Inc on Thursday filed lawsuits in Delaware federal court against Pfizer Inc and Moderna Inc, claiming their multibillion-dollar mRNA COVID-19 vaccines infringe one its patents.
Jan 1, 2022 | devdiscourse.comModerna Therapeutics Inc. launches respiratory combination vaccine program
Moderna said it is launching a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults.
Jan 1, 2022 | morningstar.comModerna Therapeutics Inc. receives award Facility of the Year Award
But on that day the Norwood plant of Moderna, Inc. received the Facility of the Year Award from the International Society for Pharmaceutical Engineering.
Jan 1, 2022 | smartindustry.comModerna Therapeutics Inc. launched two-dose pediatric coronavirus vaccine on Mar 23rd 22'.
Vaccine maker Moderna announced Wednesday its two-dose pediatric coronavirus vaccine was safe in young children, toddlers and babies in a study.
Jan 1, 2022 | washingtonpost.comModerna Therapeutics Inc. has issues with patent infringement lawsuit
Covid-19 vaccine producer Moderna faces a patent infringement lawsuit in the US, relating to the lipid nanoparticles (LNPs) that protect the mRNA in its vaccine.
Jan 1, 2022 | chemistryworld.comModerna Therapeutics Inc. is developing vaccines against 15 different pathogens on Mar 10th 22'.
This week Moderna announced plans to develop vaccines against 15 different pathogens that either have the potential to cause a pandemic or are an ongoing thorn in humanity’s side.
Jan 1, 2022 | singularityhub.comModerna Therapeutics Inc. launches clinical and program updates demonstrating expansion and advancement of mRNA pipeline
Moderna Inc., a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline.
Jan 1, 2022 | baystreet.caModerna Therapeutics Inc. launches program, mRNA Access
Second, to accelerate research with the aim of advancing additional vaccines, Moderna is launching a new program, mRNA Access that will offer researchers use of Moderna's mRNA technology to explore new vaccines against emerging or neglected infectious disease.
Jan 1, 2022 | modernatx.comModerna Therapeutics Inc. launches Phase 3 study of vaccine
Beyond its COVID-19 vaccine, Moderna Therapeutics Inc. launched the second pivotal trial in its company’s history with CMVictory, a Phase 3 study of its vaccine to prevent congenital cytomegalovirus, or CMV, which is the number one cause of birth defects in the U.S.
Jan 1, 2021 | modernatx.comModerna Therapeutics Inc. launched Moderna’s AI Academy on Dec 9th 21'.
Today, Moderna Therapeutics Inc. announced the launch of Moderna’s AI Academy in partnership with Carnegie Mellon University (CMU).
Jan 1, 2021 | modernatx.comModerna Therapeutics Inc. receives financing of $100M in funding
Under the framework agreement, the Bill & Melinda Gates Foundation granted Moderna up to $100 million in funding for “follow-on projects” that can only be approved by the Gates Foundation.
Jan 1, 2022 | dcdirtylaundry.comModerna Therapeutics Inc. receives financing of $2B in grant funds
Moderna Therapeutics has raised nearly $2 billion on the promise that messenger RNA, the molecule that relays genetic instructions from DNA to a cell's proteinmaking machinery, could be re-engineered into a versatile set of drugs and vaccines
Jan 1, 2017 | sciencemag.orgModerna Therapeutics Inc. will hire Jorge Gomez as chief financial officer on May 9th 22'.
Moderna Inc. named Jorge Gomez its new chief financial officer, succeeding David Meline who the company said will retire but remain on as a consultant to ensure a smooth transition.
Jan 1, 2022 | marketwatch.comModerna Therapeutics Inc. is developing vaccine for the virus on Feb 25th 22'.
Among them, Moderna Inc. became one of the front-runners in the race to develop a vaccine for the virus after this week announcing that its mRNA-based shot is moving into phase III development.
Jan 1, 2022 | bioworld.comModerna Therapeutics Inc. invests into assets : manufacturing facility in the amount of $500M in Kenya
Moderna plans to invest about $500 million in a manufacturing facility in Kenya and supply as many as 500 million doses of mRNA vaccines to the African continent each year, Bergstedt said.
Jan 1, 2022 | northeastern.eduModerna Therapeutics Inc. is developing mRNA COVID vaccine
Moderna received substantial US government funding— approximately $10 billion, which includes almost the entire cost of clinical development and the purchase of 500 million doses—to develop a mRNA COVID-19 vaccine.
Jan 1, 2022 | doctorswithoutborders.orgModerna Therapeutics Inc. hired Arpa Garay as Chief Commercial Officer on Mar 27th 22'.
CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join Moderna as Chief Commercial Officer, effective Monday, May 31, 2022.
Jan 1, 2022 | modernatx.comModerna Therapeutics Inc. expanded facilities to Quebec, Canada on Apr 27th 22'.
Moreover, last week Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec to support a long-term strategic partnership with the Government of Canada.
Jan 1, 2022 | ig.comModerna Therapeutics Inc. launches clinical data on bivalent COVID-19 booster platform
Moderna have announced new clinical data on its bivalent COVID-19 booster platform including data on the company’s first bivalent booster candidate, mRNA-1273.211.
Jan 1, 2022 | europeanpharmaceuticalreview.comJorge Gomez leaves Moderna Therapeutics Inc. as chief financial officer
Moderna Inc. on Wednesday said Jorge Gomez, who joined the vaccine maker this week as chief financial officer, has left amid an investigation by his former employer, Dentsply Sirona Inc., into matters that include financial reporting.
Jan 1, 2022 | marketwatch.comModerna Therapeutics Inc. hires Jorge as member of the Executive Committee
"I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee.
Jan 1, 2022 | aldianews.comModerna Therapeutics Inc. partners with Chiesi Global Rare Diseases
Moderna has entered a collaboration agreement with Chiesi Farmaceutici to develop new messenger RNA-based therapies for pulmonary arterial hypertension (PAH).
Jan 1, 2020 | pulmonaryhypertensionnews.comModerna Therapeutics Inc. is developing potential vaccines against monkeypox
Moderna Inc is testing potential vaccines against monkeypox in pre-clinical trials as the disease spreads in the United States and Europe.
Jan 1, 2022 | wkzo.comBurnet partners with Moderna Therapeutics Inc.
Burnet Institute is to partner with world-leading mRNA vaccine manufacturer Moderna, through their cutting-edge mRNA Access program, to develop novel mRNA vaccines for a range of emerging and neglected infectious diseases aimed at improving the health of communities globally.
Jan 1, 2022 | burnet.edu.auModerna Therapeutics Inc. partners with NBA
Moderna partnered with the NBA and NHL to sponsor a “shot of the game,” in which the call to action drove fans to vaccine.com to see where to get a booster.
Jan 1, 2022 | fortune.comModerna Therapeutics Inc. launches mRNA-based Covid-19 vaccine, mRNA-1273
Moderna Inc. announced that booster doses of its mRNA-based Covid-19 vaccine, mRNA-1273, appeared to substantially increase neutralizing antibodies against the SARS-CoV-2 Omicron variant, with a new 100 μg booster offering the best protection.
Jan 1, 2021 | physiciansweekly.comModerna Therapeutics Inc. launched Enterprise Solutions Hub on Mar 1st 22'.
In March 2022, Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced plans to establish a new Enterprise Solutions Hub in Atlanta.
Jan 1, 2022 | seatlantanews.comModerna Therapeutics Inc. expands offices in United Kingdom
Additionally, Moderna plans to expand its presence in the UK through investments in research and development (R&D) activities.
Jan 1, 2022 | modernatx.comModerna Therapeutics Inc. is developing mRNA vaccines for COVID-19, influenza
Moderna to establish a UK mRNA Innovation and Technology Centre to produce mRNA vaccines for COVID-19, influenza, respiratory syncytial virus (RSV) and more.
Jan 1, 2022 | europeanpharmaceuticalreview.comModerna Therapeutics Inc. partners with Usgovsolutions
Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222.
Jan 1, 2022 | pharmaceutical-technology.comModerna Therapeutics Inc. is developing combination coronavirus and flu vaccine
Additionally, Moderna is working on a candidate for a combination coronavirus and flu vaccine.
Jan 1, 2022 | friscoreports.comAsofarma CA partners with Moderna Therapeutics Inc.
As part of the agreement reached, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support for pharmacovigilance activities, continuing medical education, government affairs, marketing, and generation of new agreements that facilitate the availability of SPIKEVAX in the region.
Feb 21, 2022 | asofarma-ca.comModerna Therapeutics Inc. recognized as top biopharmaceutical employer by Science
Moderna has been named a top biopharmaceutical employer by Science for the past seven years.
Dec 22, 2021 | worldpharmatoday.comModerna Therapeutics Inc. files suit against Pfizer, Inc.
Moderna is suing Pfizer and its German partner BioNTech for alleged patent infringement in the development of the first COVID-19 vaccine approved in the US.
Aug 25, 2022 | sky.comModerna Therapeutics Inc. files suit against Biontech
Pharmaceutical giant Moderna has filed lawsuits against competitors Pfizer and BioNTech, claiming they "copied" technology used to create its coronavirus vaccine and infringed patents linked to the immunization.
Aug 26, 2022 | germanynews.netModerna Therapeutics Inc. files suit against Pfizer-BioNTech
Moderna filed a lawsuit against Pfizer and BioNTech claiming the biopharmaceutical companies infringed on Moderna’s patents related to mRNA technology in development of their COVID-19 vaccine.
Aug 25, 2022 | techcrunch.comModerna Therapeutics Inc. is developing vaccine for the novel coronavirus
Moderna Inc, on its own, and the partnership of Pfizer Inc and BioNTech SE were two of the first groups to develop a vaccine for the novel coronavirus.
Aug 25, 2022 | perthnow.com.auModerna Therapeutics Inc. filed suit against BioNTech AG on Aug 26th 22'.
Moderna filed multiple lawsuits against Pfizer and BioNTech, alleging on Friday that their Comirnaty vaccine “unlawfully infringes patents Moderna filed between 2010 and 2016.”
Aug 25, 2022 | linksbridge.comModerna Therapeutics Inc. launches multi-valent combination influenza, covid and RSV injection with mRNA technology
Moderna also announced plans to unveil a multi-valent combination influenza, covid and RSV injection with mRNA technology that it claims could change the “immunizations landscape.”
Sep 3, 2022 | dcclothesline.comModerna Therapeutics Inc. had issues with patent rights pertaining to COVID-19 vaccines globally on Oct 1st 20'.
In October 2020, Moderna announced a voluntary moratorium on enforcing its patent rights pertaining to COVID-19 vaccines globally.
Feb 28, 2022 | dennemeyer.comModerna Therapeutics Inc. is developing COVID-19 vaccine
Moderna catapulted into public consciousness after developing an effective COVID-19 vaccine in less than a year.
Aug 25, 2022 | casselsalpeter.comModerna Therapeutics Inc. launches Watch List
Moderna Inc. is trying to fend off rival companies’ claims that its Covid-19 vaccine infringes their patents, arguing that the… StockXpo’s Watch List has been launched in Oct 2020, but StockXpo has been tracking since 2015 and back testing since 2001.
Sep 19, 2022 | stockxpo.comModerna Therapeutics Inc. hires Jerh Collins as chief technical operations and quality officer overseeing vaccine manufacturing
Simultaneously, Moderna hired Novartis executive Jerh Collins, Ph.D., to fill Andres’ job as the new chief technical operations and quality officer.
Sep 29, 2022 | fiercepharma.comModerna Therapeutics Inc. launches DTC commercial
(Teka77/Getty Images) As mRNA rivals Pfizer and its partner BioNTech kick off their COVID booster ad campaign this NFL season, Moderna is also keeping up and launching a new DTC commercial.
Sep 30, 2022 | fiercepharma.comModerna Therapeutics Inc. hires Jerh
"Jerh joins Moderna with three decades of experience in global pharmaceutical manufacturing roles, including managing several manufacturing plants and as a Site Head.
Sep 29, 2022 | modernatx.comModerna Therapeutics Inc. sells assets to Usgovernmentquiz
The US government has purchased 105 million bivalent Covid-19 vaccine booster doses from Pfizer, and another 66 million updated shots from Moderna.
Aug 23, 2022 | crossroadstoday.comModerna Therapeutics Inc. is developing personalized cancer vaccine on Jan 1st 16'.
Inc. exercised its option to jointly develop and commercialize a personalized cancer vaccine with Moderna in a deal the two companies inked in 2016.
Oct 12, 2022 | bioworld.comUmassmed partnered with Moderna Therapeutics Inc. on Mar 22nd 22'.
UMass Chan Medical School today announced a research collaboration with Moderna, Inc. (Nasdaq: MRNA ), a biotechnology company pioneering messenger RNA (mRNA)-based therapeutics and vaccines, on a comprehensive study of cytomegalovirus (CMV) transmission in group childcare, education, and household settings.
Mar 22, 2022 | prnewswire.comModerna Therapeutics Inc. launched COVID-19 vaccine on Nov 7th 22'.
American biotechnology company Moderna announced Monday that a booster dose of its bivalent COVID-19 vaccine performs better against two circulating versions of the omicron variant, compared with a booster shot of its original formula.
Mar 23, 2022 | yahoo.comModerna Therapeutics Inc. hired David Meline as General Manager, United States on Apr 12th 22'.
Moderna said its recently retired CFO David Meline will come out of retirement as of May 11 while the company conducts a new CFO search.
Nov 17, 2022 | marketwatch.comModerna Therapeutics Inc. received financing of $604M in IPO on Dec 6th 18'.
Moderna raised $604 million in its IPO on Dec. 6.
Dec 6, 2018 | reuters.comModerna Therapeutics Inc. received financing of $450M in funding round on Jan 1st 15'.
In 2015 the personalized medicine startup Moderna Therapeutics raised $450 million in a funding round, the largest biotech funding round ever.
Aug 23, 2016 | medium.comModerna Therapeutics Inc. received financing of $125M in funding on Mar 5th 18'.
Moderna Therapeutics received an additional $125 million in funding through an expanded partnership with Merck around a personalized cancer vaccine.
May 3, 2018 | cnbc.comModerna Therapeutics Inc. received financing of $500M in funding round on Feb 1st 18'.
Moderna Therapeutics Inc. has filed for an IPO with a placeholder value of $500 million, potentially making it the largest American biotech IPO.
Jan 31, 2018 | seekingalpha.comModerna Therapeutics Inc. went public on Dec 6th 18'.
Moderna launched its initial public offering ( IPO ) on 6 December 2018, raising more than $605m.
Nov 22, 2022 | capital.comMarcello Damiani retired from Moderna Therapeutics Inc. as chief information officer on Dec 8th 22'.
The company also announced this week that it has appointed Brad Miller to serve as chief information officer, replacing Marcello Damiani, who is retiring after more than seven years at Moderna.
Dec 8, 2022 | mmm-online.comModerna Therapeutics Inc. hired Brad Miller as Executive Vice President and Chief Information Officer on Jan 3rd 22'.
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Brad Miller as Chief Information Officer effective January 3.
Dec 7, 2022 | medicalbuyer.co.inModerna Therapeutics Inc. will develop mRNA jab for RSV on Jan 1st 23'.
Suppression of Type 1 interferon signaling appears to be one of the primary mechanisms by which the shot destroys immune competence, and repeated booster shots can reliably be anticipated to amplify adverse effects Considering hospitalization rates for RSV are actually lower than historical seasonal highs, one also wonders whether the media’s attention on RSV might be related to the fact that Moderna is working on an mRNA jab for RSV, which is scheduled for release in 2023.
Oct 23, 2022 | prepareforchange.netModerna Therapeutics Inc. hired Chantal Friebertshäuser as SVP of commercial for Europe, the Middle East and Canada on Dec 20th 22'.
Moderna announced Tuesday that it has hired Chantal Friebertshäuser as SVP of commercial for Europe, the Middle East and Canada.
Dec 20, 2022 | mmm-online.comModerna Therapeutics Inc. expands facilities to United Kingdom
Moderna, Inc. has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK.
Dec 22, 2022 | europeanpharmaceuticalreview.comModerna Therapeutics Inc. expands facilities to Canada
In addition to a planned manufacturing site in the U.K., Moderna is building manufacturing facilities in Africa, Australia and Canada.
Dec 22, 2022 | fiercepharma.comBmmagazine partners with Moderna Therapeutics Inc.
“It is vital Bmmagazine invest in fighting future variants of this disease as well as other deadly viruses that are circulating, such as seasonal flu and RSV, and this partnership with Moderna will also strengthen its ability to respond to any future pandemics.
Dec 22, 2022 | bmmagazine.co.ukModerna Therapeutics Inc. is developing single-dose vaccine
Moderna is also working on a single-dose vaccine that would that "combines a booster dose against COVID-19 with its experimental flu shot," according to Reuters.
Dec 23, 2022 | mor-tv.comModerna Therapeutics Inc. is developing mRNA vaccines for emerging pathogens on Dec 19th 21'.
This past year, Moderna announced an initiative to develop mRNA vaccines for emerging pathogens and the Coalition for Epidemic Preparedness Innovations announced an effort to build a mRNA vaccine library against Disease X (the next pathogen with epidemic or pandemic potential that has been yet to be identified).
Dec 18, 2022 | ghtcoalition.org